Silverarc Capital Management »

Erasca shares owned by Silverarc Capital Management

Quarter-by-quarter ownership of Erasca (ERAS) shares owned by Silverarc Capital Management from 13F filings

Historical chart of Silverarc Capital Management investment in Erasca

Tip: Access up to 7 years of quarterly data

All positions including Erasca held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Erasca by Silverarc Capital Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $18M 7.8M 2.36
2024-03-31 $461k 224k 2.06
2021-09-30 $2.0M 93k 21.22

More positions owned by Silverarc Capital Management

Merus N V (MRUS)
Nuvalent Inc-a (NUVL)
Avidity Biosciences Ord (RNA)
Urogen Pharma (URGN)
Erasca (ERAS)
Insmed Call Call Option
Morphic Hldg (MORF)
Akero Therapeutics (AKRO)
Celldex Therapeutics Com New (CLDX)
Intra Cellular Therapies (ITCI)
Poseida Therapeutics I (PSTX)
Cogent Biosciences (COGT)
Insmed Com Par $.01 (INSM)
Alnylam Pharmaceuticals (ALNY)
Elutia Cl A Com (ELUT)

View all positions for Silverarc Capital Management

Top funds holding Erasca

VR Adviser
Frazier Life Sciences Management
Suvretta Capital Management
Arch Venture Corp
BlackRock
Vanguard Group
Artal Group
Henderson Group
Silverarc Capital Management
T. Rowe Price Investment Management
Paradigm Biocapital Advisors
Logos Global Management
5AM Venture Management
Partner Fund Management
Balyasny Asset Management

View all funds holding Erasca